Overview of IP Law in Canada – The Intellectual Property Review, 11th Edition

Photo of Caroline HenriePhoto of Kristin WallBy Caroline Henrie and Kristin Wall on Posted in Intellectual property
The recently published Eleventh Edition of the Intellectual Property Review (the Review) includes a Canadian chapter. Readers are invited to learn more on the various forms of IP protection available in Canada, and highlights of important changes in Canadian IP law over the past year. The chapter was authored by members of the Pharma in Brief team. The chapter … Continue reading

Federal Court finds salt patent valid in a PM(NOC) action regarding sitagliptin

Photo of Colin HyslopPhoto of Christopher A. GuerreiroPhoto of Brian R. DaleyBy Colin Hyslop, Christopher A. Guerreiro and Brian R. Daley on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
The Federal Court has allowed an infringement action concerning sitagliptin phosphate monohydrate products under the Patented Medicines (Notice of Compliance) Regulations (the Regulations). The Court dismissed allegations of obviousness and insufficiency, and it found the asserted claims to be valid and infringed. In reaching its decision, the Court provided substantive guidance on hearsay evidence in infringement … Continue reading

Federal Court sends NOC dispute concerning data protection provisions back to the Minister for a second redetermination

Photo of Colin HyslopPhoto of Christopher A. GuerreiroPhoto of Kristin WallBy Colin Hyslop, Christopher A. Guerreiro and Kristin Wall on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
The Federal Court (FC) has granted an application for judicial review involving the data protection provisions in section C.08.004.1 of the Food and Drug Regulations in a case involving new drug submissions (NDSs) for two different amifampridine products. This is the second time that the FC has set aside a decision to issue a notice … Continue reading

New interim order continues expedited authorization pathway for COVID-19 medical devices

Photo of Sarah PenningtonPhoto of John GreissPhoto of Kristin WallBy Sarah Pennington, John Greiss and Kristin Wall on Posted in Life sciences and healthcare, Pharmaceuticals and life sciences
The Minister of Health has issued a new interim order regarding expedited authorizations for COVID-19-related medical devices. Interim Order No. 3 Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19 (IO No. 3) maintains all of the flexibilities of its predecessor, including the consideration of urgent public health needs (UPHN). … Continue reading

Federal Court rejects motion for summary judgment in Canadian patent infringement case following voluntary dismissal of parallel US litigation

Photo of Colin HyslopPhoto of Christopher A. GuerreiroPhoto of Brian R. DaleyBy Colin Hyslop, Christopher A. Guerreiro and Brian R. Daley on Posted in Intellectual property
In a recently released decision, the Federal Court (FC) considered what happens when a patent infringement plaintiff agrees to resolve a dispute in a foreign jurisdiction, but continues to press parallel litigation against the same defendant in Canada. In this case, the defendant sought summary judgment based on the terms of a voluntary dismissal between the … Continue reading

Federal Court finds patent valid, but rejects infringement claims in a PM(NOC) action regarding risedronate

Photo of Sarah PenningtonPhoto of Christopher A. GuerreiroPhoto of Kristin WallBy Sarah Pennington, Christopher A. Guerreiro and Kristin Wall on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
The Federal Court has decided an infringement action concerning risedronate products under the Patented Medicines (Notice of Compliance) Regulations (the Regulations). The Court dismissed allegations of anticipation based on prior art, as well as arguments that the asserted claims were invalid due to lack of demonstrated utility, insufficiency of disclosure, and/or overbreadth. However, the Court … Continue reading

CADTH advisory panel consults on framework for pan-Canadian formulary

Photo of Sarah PenningtonPhoto of Paul JorgensenPhoto of Kristin WallBy Sarah Pennington, Paul Jorgensen and Kristin Wall on Posted in Uncategorized
In a recently published discussion paper, an Advisory Panel (the Panel) convened by the Canadian Agency for Drugs and Technologies in Health (CADTH) presents a proposed framework for a potential pan-Canadian formulary. The Panel is asking for feedback on the framework with an online questionnaire.  The feedback will inform a stakeholder session in spring 2022 … Continue reading

Federal Court finds inducement of infringement at summary trial under the PM(NOC) Regulations

Photo of Shantelle LaFayettePhoto of Jonathan ChongPhoto of Brian R. DaleyBy Shantelle LaFayette, Jonathan Chong and Brian R. Daley on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
The Federal Court has confirmed that issues of infringement, including by inducement, may be decided by summary trial in an infringement action under the Patented Medicines (Notice of Compliance) Regulations (the Regulations). The Court rejected the Defendant’s attempt to avoid infringement based on the scope of its abbreviated new drug submission and product monograph (PM). … Continue reading

Amendments to the Federal Courts Rules

Photo of Caroline HenriePhoto of David YiPhoto of Allyson Whyte NowakBy Caroline Henrie, David Yi and Allyson Whyte Nowak on Posted in Uncategorized
Amendments to the Federal Courts Rules (the Amended Rules) were registered on December 13, 2021 and officially published in the Canada Gazette Part II on December 22, 2021. The Amended Rules come into force on January 13, 2022. Key Changes and Additions As we previously reported, in April 2021 the Rules Committee of the Federal … Continue reading

FCA upholds patent validity, rejects argument that a soundly predicted invention must be obvious

Photo of Sarah PenningtonPhoto of Christopher A. GuerreiroPhoto of Brian R. DaleyPhoto of Kristin WallBy Sarah Pennington, Christopher A. Guerreiro, Brian R. Daley and Kristin Wall on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
The Federal Court of Appeal (FCA) has affirmed a decision of the Federal Court (FC) finding that a patent concerning glatiramer acetate (GA) is valid and would be infringed under the Patented Medicines (Notice of Compliance) Regulations. Background As we previously reported, the FC decision concerned allegations by Teva Canada Innovation and Teva Canada Limited … Continue reading
LexBlog